Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)open access

Authors
Maestri, AlvinoPark, Su EunFernandes, FionaLi, Zhongyi “Lucy”Kim, Yae-JeanKim, Yun-KyungLee, JinPark, Ji YoungKim, Dong HyunYang, GyongSeonLim, HyunjungKim, Jin OhLupinacci, RobertSterling, Tina M.Wilck, MarissaEsteves-Jaramillo, AlejandraBanniettis, Natalie
Issue Date
31-Dec-2024
Publisher
Taylor and Francis Ltd.
Keywords
infants; PCV15; pneumococcal conjugate vaccine; toddlers; Vaxneuvance™
Citation
Human Vaccines and Immunotherapeutics, v.20, no.1
Indexed
SCIE
SCOPUS
Journal Title
Human Vaccines and Immunotherapeutics
Volume
20
Number
1
URI
https://scholarx.skku.edu/handle/2021.sw.skku/109998
DOI
10.1080/21645515.2024.2321035
ISSN
2164-5515
2164-554X
Abstract
There is an ongoing burden of pneumococcal disease in children despite the use of pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite, descriptive study was designed to evaluate the safety and immunogenicity of a 3 + 1 regimen of V114 (VAXNEUVANCE™), a 15-valent PCV, in South Korean infants and toddlers. Adverse events (AEs) were reported for 14 d following any vaccination, and throughout the study period for serious AEs. Serotype-specific immunoglobulin G (IgG) response rates (proportion of participants meeting an IgG threshold value of ≥0.35 μg/mL) and geometric mean concentrations (GMCs) for the 15 serotypes at 30 d postdose 3 (PD3) and at 30 d postdose 4 (PD4) were evaluated as endpoints. Healthy infants enrolled at 42–90 d after birth were vaccinated with V114 (N = 57). The most commonly reported AEs were those solicited in the trial. The majority of reported AEs were transient and of mild or moderate intensity. Few serious AEs were reported; none were vaccine related. No participants died nor discontinued the study vaccine because of an AE. V114 was immunogenic for all 15 serotypes contained in the vaccine, as assessed by IgG response rates at 30 d PD3 and IgG GMCs at 30 d PD3 and at 30 d PD4. V114 was well tolerated and immunogenic when administered as a 3 + 1 regimen in healthy South Korean infants and toddlers. © 2024 Merck Sharpe Dohme. Published with license by Taylor & Francis Group, LLC.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Medicine > Department of Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher KIM, YAE JEAN photo

KIM, YAE JEAN
Medicine (Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE